Ascletis Pharma Inc (1672) investor relations material

Executive summary

• H1 2026 total income was RMB53.0m, down 48.9% YoY, and net loss widened to RMB319.7m from RMB88.0m, mainly as R&D investment more than doubled.

• Strategic focus shifted toward metabolic disease; liquidity resources of RMB2,305.4m were expected to fund operations into 2029.

Financial highlights

• Revenue from contracts with customers was RMB1.081m; total income, including other income and gains, was RMB53.0m versus RMB103.6m a year earlier.

• Net loss was RMB319.7m versus RMB88.0m; loss from operations was RMB319.5m versus RMB87.9m, and basic and diluted loss per share was RMB0.3074 versus RMB0.0914.

• R&D costs rose 132.7% YoY to RMB341.7m; administrative expenses fell 28.9% to RMB30.8m, mainly on lower staff-related costs.

• Other income and gains included RMB39.5m bank interest, RMB17.3m equity-investment gains, RMB1.2m government grants and RMB10.1m net FX loss.

• Total comprehensive loss was RMB376.8m versus RMB93.3m.

Outlook and guidance

• ASC30 obesity Phase III topline data are expected in Q3 2028; FDA NDA filing is targeted by end-2028 and EMA MAA filing in early 2029.

• ASC30 diabetes Phase II topline data are expected in Q3 2026; ASC36 oral peptide Phase I is expected to start in Q3 2026.

• Q3 2026 IND submissions are expected for ASC39, ASC30_39FDC, ASC37 injection and oral tablet, and ASC36_37FDC; ASC30_48FDC and ASC30_48_39FDC submissions are targeted for Q4 2026.

• ASC36 and ASC35 injectable peptide PK data are expected by end-2026; ASC36_35FDC PK data are expected at the start of Q1 2027.

• Cash resources are expected to support operations into 2029, beyond anticipated ASC30 NDA and MAA submissions.